Michael Midmer, MSc, MBA
Chief Executive Officer
Michael has over 15 years of experience in the life science industry, fund management and corporate finance. Michael was formerly the Director of the Genomic Applications Partnership Program (GAPP) at Genome Canada. The GAPP program funded partnerships between industry and academia including companies such as Xagenic, Vasomune, Assurex and Roche.
Before joining Genome Canada, Michael was a Director at Rosetta Capital, an international venture capital firm, where he managed a portfolio of over 30 companies in North America and Europe including company exits such as Enobia, Cytochroma, Ambit and Resonant. Michael was also Business Development Manager at KS Biomedix and was Investor Relations Manager at Cardiome Pharma. In addition, Michael has been a board member for several companies and was the Chair of a not-for-profit board.
Michael has an MSc in molecular biology from the University of Toronto (Canada) and an MBA from Imperial College Business School (UK). He has also completed the Canadian Securities Course.
Richard Liggins, PhD
Chief Scientific Officer
Richard is the Senior Director, Advanced Projects and Head, Analytical Chemistry at The Centre for Drug Research and Development (CDRD). With 15 years of industrial drug development experience, he has expertise in formulation optimization and scale-up. Richard has developed intellectual property in diverse technology areas including formulation composition, processing methods, and therapeutic methods, with over 70 US and international patents and patent applications filed in 12 patent families (five issued). With a background in both drug and device development, Dr. Liggins has contributed to CMC development in clinical IND & IDE filings (from pre-clinical research through to GMP manufacture of Phase III materials). He holds an adjunct professor appointment at the University of British Columbia, and previously was a scientist at Angiotech Pharmaceuticals.
Michael Riddell, PhD
Chair, Clinical Advisory Board
Dr. Riddell is a Professor in the School of Kinesiology & Health Science and Muscle Health Research Centre at York University in Toronto. Michael is also Senior Scientist at LMC Diabetes & Endocrinology and the Director of Education for the Diabetes Dskate Hockey and Type 1 Diabetes Program. His research interests are focused on the metabolic and hormonal responses to exercise and stress in diabetes, publishing over 120 original research papers and 18 book chapters on the topic. Dr. Riddell has a PhD in Medical Sciences from McMaster University (supervisor Dr. Oded Bar-Or) and post-doctoral training in Physiology from the University of Toronto (mentor Dr. Mladen Vranic). He is the recipient of the Faculty of Health Dean’s Established Career Research Award (2012) and is considered an international expert on exercise management and hypoglycemia prevention in type 1 diabetes. He is a contributing author to the Canadian Diabetes Association Clinical Practice Guidelines and to the International Society of Pediatric Diabetes Clinical Practice Consensus Guidelines.
With funding from NIH, JDRF, NSERC and a variety of industry partners, Dr Riddell’s laboratory uses research techniques that span from cell culture to rodent and human studies to help discover how exercise, stress and diabetes influence energy metabolism.
Susan Peers, PhD
Director of Clinical and Regulatory Affairs
Susan Peers, PhD, is a life sciences executive with drug development expertise developed over 25 years in the pharmaceutical industry including 20 years in regulatory affairs. Most recently Susan was Director, Regulatory Affairs at Transition Therapeutics ULC, a subsidiary of OPKO Health, Inc. in Toronto, ON. In her previous position in OPKO Renal (formerly Cytochroma Inc.) she was responsible for regulatory function concerning drug development, including development and submission strategy, and NDA planning and preparation.
Prior to Cytochroma, Susan had progressive roles within NPS Pharmaceutics/NPS Allelix where she was the regulatory affairs representative on project team for recombinant product in phase 3 (CDER, gastrointestinal, two indications). She was also with Resolution Pharmaceuticals, and Allelix Biopharmaceuticals.
Susan Peers has a PhD (Pharmacology) and a BSc (Pharmacology, First Class Honours) from the University of London, King’s College, UK.